Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. (JOURNAL OF CLINICAL ONCOLOGY, 2010)

(untitled) - Macaulay, V; Middleton, MR; Eckhardt, S; Juergens, R; Stephens, A; Poondru, S; McCarthy, S; Gadgeel, S